Table 3 Core American College of Rheumatology component responses at baseline and 1 year.
| ACR component | Abatacept 2 mg/kg+etanercept (n = 85) | Placebo+etanercept (n = 36) | ||||
|---|---|---|---|---|---|---|
| BL | 1 year | Change | BL | 1 year | Change | |
| Tender joints* | 28.7 (14.0) | 17.1 (17.3) | −11.6 (13.9)† | 29.2 (13.2) | 20.4 (15.1) | −8.8 (13.7)† |
| Swollen joints‡ | 19.6 (9.4) | 11.8 (9.5) | −7.8 (9.5)† | 20.1 (10.5) | 15.7 (10.6) | −4.4 (9.2)§ |
| Patient assessment of pain | 65.5 (16.6) | 43.6 (28.2) | −22.0 (29.0)† | 53.2 (23.2) | 47.0 (29.9) | −6.1 (23.2) |
| Patient assessment of function (mHAQ) | 1.0 (0.5) | 0.7 (0.6) | −0.3 (0.5)† | 0.9 (0.5) | 0.8 (0.5) | −0.2 (0.4)¶ |
| Patient assessment of disease activity | 61.6 (18.9) | 43.4 (28.0) | −18.2 (29.1)† | 54.4 (22.5) | 47.4 (29.3) | −7.1 (21.3) |
| Physician assessment of disease activity | 61.8 (17.2) | 36.2 (23.7) | −25.7 (27.0)† | 62.1 (13.5) | 43.8 (28.3) | −18.2 (20.4)† |
| CRP** | 2.0 (2.6) | 1.4 (1.5) | −0.6 (2.4)†† | 2.4 (4.3) | 3.3 (4.9) | −0.9 (3.5) |
ACR, American College of Rheumatology; BL, baseline; CRP, C reactive protein; mHAQ, modified Health Assessment Questionnaire.
All patients received etanercept 25 mg twice weekly.
All values are shown as mean (SD).
*68 joints were assessed for tenderness; †p<0.001; ‡66 joints were assessed for swelling; §p = 0.007; ¶p = 0.040; **reference range 0–0.4 mg/dl; ††p = 0.039.